STALICLA

📍 Genève, Switzerland🗓 Founded 2017👥 21 employees💰 Last funded Oct 2025
Biotechnology Research🌐 stalicla.com
Website LinkedIn
STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLAs first patient subgroup-matched precision treatment. Substance Use Disorder research: STALICLA is working in partnership with the National Institute of Drug Abuse (NIDA) to advance Phase 3 clinical trials for the most clinically advanced drug candidate for cocaine abuse disorder, STP7. STALICLA is now raising series C funding to advance both verticals. For more information visit: https://stalicla.com.
4
Total investors
2
Early stage
1
Mid stage
1
Late stage
2017
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
Switzerland
2
Spain
1
United Kingdom
1
Investor activity2018–2025 · investors recorded per year
201822020120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in STALICLA?
STALICLA has 4 investors on record on gritt.io, including 2 early-stage backers, 1 mid-stage and 1 late-stage investors.
When did STALICLA last raise funding?
The most recent investment in STALICLA recorded on gritt.io was in October 2025.
When was STALICLA founded?
STALICLA was founded in 2017.
What industry is STALICLA in?
STALICLA operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is STALICLA based?
STALICLA is headquartered in Genève, Switzerland.